Rezultate promițătoare pentru un vaccin împotriva cancerului pancreatic testat pentru prima dată pe oameni

An experimental vaccine for pancreatic cancer prevention showed promising results in a first human trial, with no participants developing cancer during monitoring. The study involved 20 individuals at high genetic risk, and the vaccine triggered a strong immune response in 90% of them. After an average follow-up of 16.5 months, 37.5% of participants saw a reduction in pancreatic cysts. Researchers emphasize the need for larger studies to confirm these findings and assess clinical efficacy.